A new FREE TO ATTEND webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More
Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study. Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
A new FREE TO ATTEND webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More
Niven R Narain, President and CEO, BPGbio, looks at how biology-first Bayesian causal AI is redefining success in drug development. From using AI-based computational modelling to phase out animal testing for monoclonal antibodies1, to deploying its proprietary large language model-powered tool, Elsa, to read, write, and summarise regulatory documents—reducing review time… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move… Read More
A new FREE TO ATTEND webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More
Veronica DeFelice, Director of Biologic Products at Sapio Sciences, looks at how the hit-to-lead process in drug discovery is being impacted by AI and automation. Complexity at the core of hit-to-lead Hit-to-lead (H2L) screening is a critical phase in drug discovery, where researchers narrow down large libraries of compounds, small… Read More
Discover how the Agilent BioTek Cytation cell imaging multimode reader and ViQi’s AVIA provide a powerful, integrated solution for viral infectivity analysis. Download the Application Note to explore how this innovative approach offers key advantages over traditional assays, including: High-throughput, cost-effective analysis: AVIA minimises reagent use, incubation time, and replicate… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
A new free to attend webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More
In this FREE TO ATTEND webinar, hosted by DDW and supported by Sapio Sciences, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational methods, AI, and machine learning are revolutionising drug discovery. Dr Kumar highlights how Schrödinger’s physics-based simulations and Free Energy… Read More
CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery. The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK. The combined platform aims… Read More
Andrew Anderson, Vice President, Innovation and Informatics Strategy at ACD/Labs, looks at how AI is enabling true drug design. Innovators in the pharma and biopharma sectors are actively seeking systems that accelerate the discovery, development, and commercialisation of new products. Of particular interest are systems to support the implementation of… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
DDW Editor Reece Armstrong speaks to Josh Mandel-Brehm, CEO of CAMP4 Therapeutics, about challenges in the discovery and development of RNA therapeutics. RA: Why has regulatory RNA historically not been exploited as a therapeutic target? JMB: Historically, RNA has been viewed primarily as a messenger — a passive intermediary… Read More
A team at Standford have created CRISPR-GPT, a large language model (LLM) agent system to automate and enhance CRISPR-based gene-editing design and data analysis. CRISPR-GPT leverages the reasoning capabilities of LLMs for complex task decomposition, decision-making and interactive human–artificial intelligence (AI) collaboration. The system incorporates… Read More
